Halozyme Therapeutics, Inc. (HALO) P/E Ratio History
ExpensiveTrading at 31.9x vs 5Y avg 20.4x · 95th percentile · Material premium to history · Data 2017–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Halozyme Therapeutics, Inc. (HALO) trades at a price-to-earnings ratio of 31.9x, with a stock price of $81.57 and trailing twelve-month earnings per share of $2.84.
The current P/E is 56% above its 5-year average of 20.4x. Over the past five years, HALO's P/E has ranged from a low of 11.9x to a high of 39.2x, placing the current valuation at the 95th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, HALO trades at a 36% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
The PEG ratio of 1.39 (P/E divided by -25% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, HALO commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HALO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HALO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HALO P/E vs Peers
Drug Delivery Technology Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $43B | 138.0 | - | +207% | |
| $14B | 20.5 | 0.40Best | +58% | |
| $2B | 6.7Lowest | 0.65 | +817%Best | |
| $450B | 107.4 | - | -1% | |
| $199B | 25.9 | 8.79 | +88% | |
| $70B | 16.3 | 2.58 | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HALO Historical P/E Data (2017–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $64.63 | $2.78 | 23.2x | -26% |
| FY2025 Q4 | Dec 31 2025 | $67.30 | $2.49 | 27.0x | -14% |
| FY2025 Q3 | - | $73.34 | $4.75 | 15.4x | -51% |
| FY2025 Q2 | Jun 30 2025 | $52.02 | $4.37 | 11.9x | -62% |
| FY2025 Q1 | Mar 31 2025 | $63.81 | $3.76 | 17.0x | -46% |
| FY2024 Q4 | - | $47.81 | $3.43 | 13.9x | -56% |
| FY2024 Q3 | Sep 30 2024 | $57.24 | $3.02 | 19.0x | -40% |
| FY2024 Q2 | Jun 30 2024 | $52.36 | $2.58 | 20.3x | -35% |
| FY2024 Q1 | Mar 31 2024 | $40.68 | $2.42 | 16.8x | -47% |
| FY2023 Q4 | Dec 31 2023 | $36.96 | $2.11 | 17.5x | -44% |
| FY2023 Q3 | Sep 30 2023 | $38.20 | $1.88 | 20.3x | -35% |
| FY2023 Q2 | Jun 30 2023 | $36.07 | $1.71 | 21.1x | -33% |
| FY2023 Q1 | Mar 31 2023 | $38.19 | $1.31 | 29.2x | -7% |
| FY2022 Q4 | Dec 31 2022 | $56.90 | $1.45 | 39.2x | +25% |
| FY2022 Q3 | Sep 30 2022 | $39.54 | $1.49 | 26.5x | -16% |
| FY2022 Q2 | - | $44.00 | $2.53 | 17.4x | -45% |
| FY2022 Q1 | - | $39.88 | $2.99 | 13.3x | -58% |
| FY2021 Q4 | Dec 31 2021 | $40.21 | $2.75 | 14.6x | -53% |
| FY2021 Q3 | - | $40.68 | $2.79 | 14.6x | -54% |
| FY2021 Q2 | Jun 30 2021 | $45.41 | $1.56 | 29.1x | -7% |
| FY2021 Q1 | Mar 31 2021 | $41.69 | $1.13 | 36.9x | +17% |
| FY2020 Q4 | - | $42.71 | $0.90 | 47.7x | +52% |
| FY2020 Q3 | Sep 30 2020 | $26.28 | $0.16 | 169.0x | +437% |
| FY2018 Q3 | Sep 30 2018 | $18.17 | $0.31 | 58.6x | +86% |
| FY2018 Q2 | Jun 30 2018 | $16.87 | $0.52 | 32.4x | +3% |
| FY2018 Q1 | Mar 31 2018 | $19.59 | $0.45 | 43.5x | +38% |
| FY2017 Q4 | Dec 31 2017 | $20.26 | $0.38 | 53.3x | +70% |
Average P/E for displayed period: 31.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HALO — Frequently Asked Questions
Quick answers to the most common questions about buying HALO stock.
What is HALO's P/E ratio?
Halozyme Therapeutics, Inc. (HALO) trailing twelve-month P/E ratio is 31.9x, based on TTM diluted EPS of $2.84. The 5-year average P/E is 20.4x and the historical range spans 11.9x to 39.2x.
Is HALO stock overvalued or undervalued?
HALO trades at 31.9x P/E, above its 5-year average of 20.4x. The 95th percentile ranking within the 11.9x–39.2x historical range indicates a premium to historical valuation.
Is HALO stock expensive?
Yes, HALO is expensive relative to its own history. The current P/E of 31.9x is above the 5-year average of 20.4x and also above the Healthcare sector median of 23.4x. The stock sits at the 95th percentile of its 5-year valuation range.
What is HALO's historical P/E range?
Over the past 5 years, HALO's P/E ratio has ranged from 11.9x to 39.2x, with a median of 19.0x and an average of 20.4x. The current P/E of 31.9x places the stock at the 95th percentile of this range. Full historical data spans 2017–2026.
How does HALO's P/E compare to the S&P 500?
HALO trades at 31.9x P/E versus the S&P 500 median of 25.9x. The 23% premium to the market typically reflects higher expected earnings growth or quality.
How does HALO's valuation compare to Healthcare peers?
Halozyme Therapeutics, Inc. P/E of 31.9x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is HALO's PEG ratio?
HALO PEG ratio is 1.39, based on a P/E of 31.9x and EPS growth of -25.4%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is HALO's earnings yield?
HALO earnings yield is 3.14%, the inverse of its 31.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.